8-K: Owens & Minor Shifts Focus, Reports Q2 Net Loss

Owens & Minor reported a significant net loss in Q2 2025 due to the classification of its Products & Healthcare Services segment as discontinued operations, while its Patient Direct business showed solid growth.

Summary

• Owens & Minor, Inc. has classified its Products & Healthcare Services segment as discontinued operations in connection with a likely sale, shifting its focus to a pure-play Patient Direct business.
• The company reported a net loss of $869.0 million for the second quarter ended June 30, 2025, significantly higher than the $31.9 million net loss in Q2 2024.
• This substantial net loss includes a $785.2 million loss from discontinued operations, net of tax, and a $649.1 million loss on classification to held for sale.
• A transaction breakage fee of $80.0 million related to the terminated Rotech acquisition and $18.3 million in transaction financing fees also contributed to the loss.
• For continuing operations (primarily Patient Direct), revenue grew to $681.9 million in Q2 2025 from $660.4 million in Q2 2024.
• Adjusted net income from continuing operations increased to $20.5 million in Q2 2025 from $19.3 million in Q2 2024.
• Adjusted EBITDA from continuing operations rose to $96.6 million in Q2 2025 from $91.1 million in Q2 2024.
• Diluted GAAP loss per common share from continuing operations was $(1.09), while adjusted diluted EPS from continuing operations was $0.26.
• The company provided a full-year 2025 outlook for continuing operations, projecting revenue between $2.76 billion and $2.82 billion, and adjusted EPS between $1.02 and $1.07.

Sentiment

Score: 7

Explanation: The sentiment is cautiously positive. While the company reported a substantial GAAP net loss due to one-time charges related to the divestiture, the underlying continuing operations (Patient Direct) showed solid growth in revenue, adjusted net income, and adjusted EBITDA. The strategic shift to a pure-play Patient Direct business is viewed as a positive long-term move, aligning with favorable market trends and offering clearer strategic focus, despite the short-term financial impact of the transition.

Positives

• The Patient Direct segment, representing continuing operations, demonstrated solid performance and growth, with Q2 2025 revenue increasing to $681.9 million from $660.4 million in Q2 2024.
• Adjusted net income from continuing operations grew to $20.5 million in Q2 2025, up from $19.3 million in the prior year quarter.
• Adjusted EBITDA from continuing operations increased to $96.6 million in Q2 2025, compared to $91.1 million in Q2 2024, indicating improved operational profitability in the core business.
• The strategic decision to divest the Products & Healthcare Services segment allows the company to transition into a focused, pure-play Patient Direct business, aligning with favorable demographic trends and leveraging existing scale.
• Management expressed confidence in the company's ability to lead the evolving Patient Direct market.

Negatives

• The company reported a substantial GAAP net loss of $869.0 million for Q2 2025, a significant increase from the $31.9 million net loss in Q2 2024.
• The net loss was heavily impacted by a $785.2 million loss from discontinued operations, net of tax, and a $649.1 million loss on classification to held for sale.
• A transaction breakage fee of $80.0 million was incurred due to the termination of the Rotech acquisition.
• Transaction financing fees, net, amounted to $18.3 million, further contributing to the losses.
• GAAP loss from continuing operations, net of tax, widened to $(83.8) million in Q2 2025 from $(6.7) million in Q2 2024.
• Basic and diluted GAAP loss per common share for total operations was $(11.30) for Q2 2025, a substantial increase from $(0.42) in Q2 2024.

Risks

• There is no assurance that the sale of the Products & Healthcare Services (P&HS) business will be successfully completed on favorable terms or at all.
• Actual future results may differ materially from projected or contemplated forward-looking statements due to known and unknown risks and uncertainties.
• The company's performance is subject to macro and market conditions.
• Investors should refer to the company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent quarterly/current reports for a discussion of certain known risk factors.

Future Outlook

The company anticipates a transition into a focused, pure-play Patient Direct business, building on momentum and supported by favorable demographic trends. For the full year 2025, continuing operations are projected to achieve revenue between $2.76 billion and $2.82 billion, adjusted EBITDA between $376 million and $382 million, and adjusted EPS between $1.02 and $1.07. The company expects interest expense to be $97 million to $100 million, gross capital expenditures $205 million to $215 million, and net capital expenditures $135 million to $145 million, with an adjusted effective tax rate of 29.5% to 30.5% and approximately 80 million diluted weighted average shares outstanding.

Management Comments

• "We are in the final stages of our robust process for the divestiture of the Products & Healthcare Services segment, and, as a result, have classified this segment as discontinued operations. We are looking forward to concluding the sale of the business and working with a buyer who has the vision and greater flexibility to better support our customers and long-term growth."
• "I am excited about the opportunities ahead as we transition into a focused, pure-play Patient Direct business. Building on the momentum gained since we entered the Patient Direct space eight years ago, and supported by favorable demographic trends and meaningful scale, we are confident in our ability to lead as the market continues to evolve."

Industry Context

This announcement signifies a strategic pivot for Owens & Minor, moving away from its broader Products & Healthcare Services segment to concentrate solely on the Patient Direct business. This shift aligns with a growing trend in healthcare towards home-based care and direct-to-patient services, driven by favorable demographic trends such as an aging population and increased demand for convenient healthcare solutions. By becoming a pure-play Patient Direct company, Owens & Minor aims to capitalize on this evolving market and enhance its leadership position.

Legal Proceedings

• The company incurred 'Litigation and related charges' which include settlement costs and related charges of legal matters, noted as non-recurring/infrequent and unpredictable in timing and amount.

Stakeholder Impact

• Shareholders will experience a significant GAAP net loss in the short term due to the discontinued operations and related charges, but may benefit from the long-term strategic focus on the growing Patient Direct segment.
• Customers of the divested Products & Healthcare Services segment are expected to receive better support and long-term growth opportunities from the new buyer.
• Employees within the divested segment may experience changes in employment or management as the business transitions to a new owner.

Next Steps

• Concluding the sale of the Products & Healthcare Services segment.
• Hosting an investor conference call on August 11, 2025, at 8:30 a.m. EDT to discuss Q2 2025 financial results and provide the 2025 financial outlook for continuing operations.

Key Dates

Recommendation

The company's strategic decision to divest its Products & Healthcare Services segment and focus on the Patient Direct business is a significant long-term positive, aligning with favorable demographic trends and a growing market. While the reported GAAP net loss for Q2 2025 is substantial due to one-time charges related to the divestiture and a terminated acquisition, the underlying performance of the continuing Patient Direct operations shows solid growth in revenue and adjusted profitability. A seasoned investor would recognize these one-time charges as non-recurring and necessary for the strategic pivot. The stock is a 'hold' as the market digests the short-term financial impact versus the long-term strategic clarity and growth potential of the focused Patient Direct business. Investors should monitor the successful completion of the divestiture and the subsequent performance of the Patient Direct segment.

Keywords

Healthcare solutions, Patient Direct, Medical supplies, Divestiture, Financial results, Q2 earnings, Discontinued operations, Healthcare services, OMI